Literature DB >> 25760284

The role of p21-activated kinases in pancreatic cancer.

Dannel Yeo1, Hong He, Graham S Baldwin, Mehrdad Nikfarjam.   

Abstract

Pancreatic cancer is an aggressive cancer with a poor prognosis and an overall 5-year survival rate of less than 5%. Management has not improved significantly over the last 30 years, and a better understanding of the genetic and molecular changes that occur is urgently required. Many of these changes appear to involve the p21-activated kinases (PAKs). The PAK family consists of 6 isoforms, 2 of which, PAK1 and PAK4, are up-regulated and/or hyperactivated in pancreatic cancer. p21-Activated kinases can mediate many different cellular processes especially those contributing to cancer development and progression. These processes include the regulation of cytoskeletal dynamics and cell adhesion, the evasion of apoptosis, and the promotion of cell survival, proliferation, migration, and invasion. p21-Activated kinases may also be involved in characteristics unique to pancreatic tumors, such as interplay with the pancreatic stroma, the re-emergence of embryonic pathways, and the involvement of a subset of microRNAs and heat shock proteins. This review highlights the potential role of PAKs in pancreatic cancer and provides a foundation for more effective therapeutics to improve our current treatment of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25760284     DOI: 10.1097/MPA.0000000000000276

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  19 in total

1.  Pak1 maintains epidermal stem cells by regulating Langerhans cells and is required for skin carcinogenesis.

Authors:  Kazuhiro Okumura; Megumi Saito; Yasuhiro Yoshizawa; Yuki Ito; Eriko Isogai; Kimi Araki; Yuichi Wakabayashi
Journal:  Oncogene       Date:  2020-05-19       Impact factor: 9.867

2.  P21-activated kinase 4 in pancreatic acinar cells is activated by numerous gastrointestinal hormones/neurotransmitters and growth factors by novel signaling, and its activation stimulates secretory/growth cascades.

Authors:  Irene Ramos-Alvarez; R T Jensen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-04-19       Impact factor: 4.052

3.  Cyclic AMP-dependent protein kinase A and EPAC mediate VIP and secretin stimulation of PAK4 and activation of Na+,K+-ATPase in pancreatic acinar cells.

Authors:  Irene Ramos-Alvarez; Lingaku Lee; R T Jensen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2018-12-06       Impact factor: 4.052

4.  Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation.

Authors:  Ramzi M Mohammad; Yiwei Li; Irfana Muqbil; Amro Aboukameel; William Senapedis; Erkan Baloglu; Yosef Landesman; Philip A Philip; Asfar S Azmi
Journal:  Small GTPases       Date:  2017-06-23

5.  Bioactive compound from Lagerstroemia speciosa: activating apoptotic machinery in pancreatic cancer cells.

Authors:  Shallu Goyal; Monika Sharma; Rohit Sharma
Journal:  3 Biotech       Date:  2022-03-19       Impact factor: 2.406

6.  LIM Kinase, a Newly Identified Regulator of Presynaptic Remodeling by Rod Photoreceptors After Injury.

Authors:  Weiwei Wang; Ellen Townes-Anderson
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-12       Impact factor: 4.799

7.  Glaucarubinone Combined with Gemcitabine Improves Pancreatic Cancer Survival in an Immunocompetent Orthotopic Murine Model.

Authors:  Dannel Yeo; Nhi Huynh; John A Beutler; Graham S Baldwin; Hong He; Mehrdad Nikfarjam
Journal:  J Invest Surg       Date:  2016-03-30       Impact factor: 2.533

8.  Expression of phosphorylated p21-activated kinase 4 is associated with aggressive histologic characteristics and poor prognosis in patients with surgically treated renal cell carcinoma.

Authors:  Ho Won Kang; Xuan Mei Piao; Hee Youn Lee; Kyeong Kim; Sung Pil Seo; Yun Sok Ha; Yeong Uk Kim; Won Tae Kim; Yong June Kim; Sang Cheol Lee; Wun Jae Kim; Eun Young Shin; Eung Gook Kim; Seok Joong Yun
Journal:  Investig Clin Urol       Date:  2021-05-17

9.  FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine.

Authors:  Dannel Yeo; Hong He; Oneel Patel; Andrew M Lowy; Graham S Baldwin; Mehrdad Nikfarjam
Journal:  BMC Cancer       Date:  2016-01-16       Impact factor: 4.430

10.  Analysis of Important Gene Ontology Terms and Biological Pathways Related to Pancreatic Cancer.

Authors:  Hang Yin; ShaoPeng Wang; Yu-Hang Zhang; Yu-Dong Cai; Hailin Liu
Journal:  Biomed Res Int       Date:  2016-11-09       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.